Contineum Therapeutics, Inc. Class A Common Stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Contineum Therapeutics, Inc. Class A Common Stock generated cash of $19,349,000, which is more than the previous year. Cash used in financing activities reached the amount of $56,176,000 last year. Net change in cash is therefore $9,957,000.
Cash Flow
| 2022 | -20.12M | 22.29M | -1.23M |
|---|---|---|---|
| 2023 | 19.34M | -65.56M | 56.17M |
CTNM Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 5.56M | 4.63M |
Operating activities | ||
Net income | 22.72M | -24.25M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 195K | 329K |
Stock-based compensation expense | 2.21M | 1.92M |
| Deferred income tax benefit | 2.21M | 1.92M |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 0 | -230K |
Cash generated by operating activities | 19.34M | -20.12M |
Investing activities | ||
Purchases Of Investments | -141.86M | -64.69M |
Investments In Property Plant And Equipment | -414K | -118K |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -65.56M | 22.29M |
Financing activities | ||
Common Stock Issued | 0 | 0 |
Payments for dividends | 0 | 0 |
Repurchases of common stock | -28K | -4K |
Repayments of term debt | -3.75M | -1.25M |
Cash used in financing activities | 56.17M | -1.23M |
Net Change In Cash | 9.95M | 939K |
Cash at end of period | 15.52M | 5.56M |